Literature DB >> 16943567

Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment.

Silke Lankiewicz1, Bertha Gutierrez Rivero, Oliver Bócher.   

Abstract

Detection of disseminated tumor cells in the blood circulation is important in assessing tumor progression. The objective of this examination was to develop a highly specific and sensitive quantitative realtime reverse transcriptase-polymerase chain reaction (qRT-PCR) assay for the detection of relevant tumor-associated transcripts in patients' blood. The qRT-PCR assays detect the human epidermal growth factor receptor 2 (HER2) and CK20 transcripts of two tumor cells spiked into 5 mL of blood after an immunomagnetic tumor cell enrichment. Furthermore, the HER2 assay is only specific when enrichment is included. This procedure is a useful alternative to fluorescence in situ hybridization and immunocytochemistry for gene alteration analysis in human tumors. The analysis of the studied molecular markers of tumor cells in blood may be useful in the detection of disseminated tumor cells as well as for monitoring treatment response, early detection of relapse, and for stratification of patients with carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943567     DOI: 10.1385/MB:34:1:15

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  37 in total

1.  Properties of the reverse transcription reaction in mRNA quantification.

Authors:  Anders Ståhlberg; Joakim Håkansson; Xiaojie Xian; Henrik Semb; Mikael Kubista
Journal:  Clin Chem       Date:  2004-01-15       Impact factor: 8.327

2.  A point mutation G----A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria.

Authors:  B Grandchamp; C Picat; F de Rooij; C Beaumont; P Wilson; J C Deybach; Y Nordmann
Journal:  Nucleic Acids Res       Date:  1989-08-25       Impact factor: 16.971

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  Transcription of cytokeratins 8, 18, and 19 in bone marrow and limited expression of cytokeratins 7 and 20 by carcinoma cells: inherent limitations for RT-PCR in the detection of isolated tumor cells.

Authors:  A Dimmler; R Gerhards; C Betz; K Günther; B Reingruber; T Horbach; I Baumann; T Kirchner; W Hohenberger; T Papadopoulos
Journal:  Lab Invest       Date:  2001-10       Impact factor: 5.662

5.  Quantitative analysis of cytokeratin 20 gene expression using RT-PCR and capillary electrophoresis with fluorescent DNA detection.

Authors:  J A van Eekelen; F V Shammas; L Wee; R Heikkilä; A Osland
Journal:  Clin Biochem       Date:  2000-08       Impact factor: 3.281

6.  Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.

Authors:  D Gancberg; A Di Leo; F Cardoso; G Rouas; M Pedrocchi; M Paesmans; A Verhest; C Bernard-Marty; M J Piccart; D Larsimont
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

7.  HER-2 gene amplification can be acquired as breast cancer progresses.

Authors:  Songdong Meng; Debasish Tripathy; Sanjay Shete; Raheela Ashfaq; Barbara Haley; Steve Perkins; Peter Beitsch; Amanullah Khan; David Euhus; Cynthia Osborne; Eugene Frenkel; Susan Hoover; Marilyn Leitch; Edward Clifford; Ellen Vitetta; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Timothy Fleming; Tanja Fehm; Thomas Tucker; Nancy Lane; Jianqiang Wang; Jonathan Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-11       Impact factor: 11.205

8.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

9.  Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers.

Authors:  Ronny Schuster; Nicole Max; Benno Mann; Karin Heufelder; Florian Thilo; Jörn Gröne; Franziska Rokos; Heinz-Johannes Buhr; Eckhard Thiel; Ulrich Keilholz
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

10.  Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes.

Authors:  R Jung; K Petersen; W Krüger; M Wolf; C Wagener; A Zander; M Neumaier
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

View more
  12 in total

Review 1.  Circulating Tumor Cells in Early-Stage Breast Cancer.

Authors:  A D Hartkopf; M Banys; N Krawczyk; M Wallwiener; H Schneck; H Neubauer; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

Review 2.  CTC clusters in cancer progression and metastasis.

Authors:  Anna Fabisiewicz; Ewa Grzybowska
Journal:  Med Oncol       Date:  2016-12-23       Impact factor: 3.064

Review 3.  Nanotechnology for enrichment and detection of circulating tumor cells.

Authors:  Saheel Bhana; Yongmei Wang; Xiaohua Huang
Journal:  Nanomedicine (Lond)       Date:  2015-07       Impact factor: 5.307

4.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.

Authors:  Tanja Fehm; Oliver Hoffmann; Bahriye Aktas; Sven Becker; Erich F Solomayer; Diethelm Wallwiener; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Cancer Res       Date:  2009-08-10       Impact factor: 6.466

5.  Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.

Authors:  Mitra Tewes; Sabine Kasimir-Bauer; Anja Welt; Martin Schuler; Rainer Kimmig; Bahriye Aktas
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-10       Impact factor: 4.553

6.  Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Authors:  Natalie Turner; Marta Pestrin; Francesca Galardi; Francesca De Luca; Luca Malorni; Angelo Di Leo
Journal:  Cancers (Basel)       Date:  2014-03-25       Impact factor: 6.639

Review 7.  Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.

Authors:  Tanja Fehm; Volkmar Müller; Catherine Alix-Panabières; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2008-04-09       Impact factor: 6.466

8.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

Authors:  Tanja Fehm; Sven Becker; Silke Duerr-Stoerzer; Karl Sotlar; Volkmar Mueller; Diethelm Wallwiener; Nancy Lane; Erich Solomayer; Jonathan Uhr
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 9.  Circulating tumour cells in breast cancer.

Authors:  Natalia Krawczyk; Malgorzata Banys; Andreas Hartkopf; Carsten Hagenbeck; Carola Melcher; Tanja Fehm
Journal:  Ecancermedicalscience       Date:  2013-09-19

10.  The role and clinical relevance of disseminated tumor cells in breast cancer.

Authors:  Malgorzata Banys; Natalia Krawczyk; Tanja Fehm
Journal:  Cancers (Basel)       Date:  2014-01-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.